186 related articles for article (PubMed ID: 31991250)
1. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Garrett K; Popescu I; Pennings JS; Fowlkes JL; Nyman JS
Bone; 2020 Apr; 133():115254. PubMed ID: 31991250
[TBL] [Abstract][Full Text] [Related]
2. Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis.
Hughes CB; Mussman GM; Ray P; Bunn RC; Cornea V; Thrailkill KM; Fowlkes JL; Popescu I
Cell Tissue Res; 2021 May; 384(2):527-543. PubMed ID: 33409652
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
[TBL] [Abstract][Full Text] [Related]
4. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Popescu I; Kalaitzoglou E; Fowlkes JL; Nyman JS
Bone; 2020 Dec; 141():115625. PubMed ID: 32890778
[TBL] [Abstract][Full Text] [Related]
6. Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age.
Creecy A; Uppuganti S; Unal M; Clay Bunn R; Voziyan P; Nyman JS
Bone; 2018 May; 110():204-214. PubMed ID: 29438824
[TBL] [Abstract][Full Text] [Related]
7. Changes in the Fracture Resistance of Bone with the Progression of Type 2 Diabetes in the ZDSD Rat.
Creecy A; Uppuganti S; Merkel AR; O'Neal D; Makowski AJ; Granke M; Voziyan P; Nyman JS
Calcif Tissue Int; 2016 Sep; 99(3):289-301. PubMed ID: 27209312
[TBL] [Abstract][Full Text] [Related]
8. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
Alba M; Xie J; Fung A; Desai M
Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
[TBL] [Abstract][Full Text] [Related]
9. Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption.
Unno K; Taguchi K; Takagi Y; Hase T; Meguro S; Nakamura Y
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047250
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice.
Yildirim G; Bergamo ETP; Poudel SB; Ruff RR; Dixit M; Hu B; Mijares DQ; Witek L; Chlebek C; Harrison DE; Strong R; Miller RA; Ladiges W; Bromage TG; Rosen CJ; Yakar S
Geroscience; 2023 Jun; 45(3):1933-1951. PubMed ID: 37166526
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice.
Gerber C; Wang X; David V; Quaggin SE; Isakova T; Martin A
JBMR Plus; 2021 Aug; 5(8):e10526. PubMed ID: 34368611
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Jackson K; Moseley KF
Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428
[TBL] [Abstract][Full Text] [Related]
13. Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10.
Unno K; Yamamoto H; Toda M; Hagiwara S; Iguchi K; Hoshino M; Takabayashi F; Hasegawa-Ishii S; Shimada A; Hosokawa M; Higuchi K; Mori M
Biochem Biophys Res Commun; 2014 Nov; 454(1):89-94. PubMed ID: 25450362
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and Skeletal Characterization of the KK/A
Chowdhury NN; Surowiec RK; Kohler RK; Reul ON; Segvich DM; Wallace JM
Calcif Tissue Int; 2024 Jun; 114(6):638-649. PubMed ID: 38642089
[TBL] [Abstract][Full Text] [Related]
15. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
16. Induction and rescue of skeletal fragility in a high-fat diet mouse model of type 2 diabetes: An in vivo and in vitro approach.
LLabre JE; Sroga GE; Tice MJL; Vashishth D
Bone; 2022 Mar; 156():116302. PubMed ID: 34952229
[TBL] [Abstract][Full Text] [Related]
17. Germ-Free C57BL/6 Mice Have Increased Bone Mass and Altered Matrix Properties but Not Decreased Bone Fracture Resistance.
Vahidi G; Moody M; Welhaven HD; Davidson L; Rezaee T; Behzad R; Karim L; Roggenbeck BA; Walk ST; Martin SA; June RK; Heveran CM
J Bone Miner Res; 2023 Aug; 38(8):1154-1174. PubMed ID: 37221143
[TBL] [Abstract][Full Text] [Related]
18. Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model.
Lamantia J; Sloan K; Wallace JM; Roper RJ
Bone; 2024 Apr; 181():117046. PubMed ID: 38336158
[TBL] [Abstract][Full Text] [Related]
19. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone.
Nyman JS; Even JL; Jo CH; Herbert EG; Murry MR; Cockrell GE; Wahl EC; Bunn RC; Lumpkin CK; Fowlkes JL; Thrailkill KM
Bone; 2011 Apr; 48(4):733-40. PubMed ID: 21185416
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CaMKK2 reverses age-associated decline in bone mass.
Pritchard ZJ; Cary RL; Yang C; Novack DV; Voor MJ; Sankar U
Bone; 2015 Jun; 75():120-7. PubMed ID: 25724145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
